Shots: The P-IIIb/IV SPIRIT-H2H study results involve assessing of Taltz vs Humira (adalimumab) in 566 patients with PsA who are biologic DMARD-naive for 52wks. The P-IIIb/IV SPIRIT-H2H study results: met […]readmore
Tags : #EULAR2019
Shots: The P-IV Early AMPLE mechanistic study results involve assessing of Orencia (125 mg, SC) vs adalimumab (40mg, SC) on a background of MTX in 80 patients in a ratio […]readmore
Shots: The study results involves assessing of CT-P13 SC (90mg/120mg/180mg) vs CT-P13 IV (3mg/kg) in 50 patients in ratio (1:1:1:1) with RA, followed by a P-I/III study assessing CT-P13 SC […]readmore
Shots: The P-IIIB/IV study results involve assessing of Xeljanz XR (11 mg, qd) as monothx. followed by MTX withdrawal vs Xeljanz XR + MTX in 530 patients in ratio (1:1) […]readmore